Additionally, developing antagonists to suppress RIG-I activation could provide new therapeutics for chronic inflammation resulting from prolonged RIG-I activity [118,119] and treatments for diseases such as the Aicardi-Goutièrez Syndrome and SMS. The gene discussed is RIGI; the disease is Smith-Magenis syndrome.